Home/Filings/4/0001213900-23-074485
4//SEC Filing

Pamir Ozan 4

Accession 0001213900-23-074485

CIK 0001690080other

Filed

Sep 5, 8:00 PM ET

Accepted

Sep 6, 6:30 PM ET

Size

6.5 KB

Accession

0001213900-23-074485

Insider Transaction Report

Form 4
Period: 2023-09-04
Pamir Ozan
Interim CFO
Transactions
  • Award

    Stock Option (Right to Buy)

    2023-09-04+15,00015,000 total
    Exercise: $0.67Exp: 2033-09-04Common Stock (15,000 underlying)
Holdings
  • Common Stock

    8,983.077
Footnotes (2)
  • [F1]The Stock Options were granted to the Reporting Person pursuant to the Issuer's First Amended and Restated 2022 Omnibus Incentive Plan in consideration for services to be rendered as Chief Financial Officer. Exempt from Section 16(b) pursuant to Rule 16b-3.
  • [F2]The options vest at the rate of 1/12th of such options ratably on a monthly basis over the following 12 months on the last day of each calendar month (beginning September 30, 2023), subject to the Reporting Person's continued service to the Company on such vesting dates.

Issuer

180 Life Sciences Corp.

CIK 0001690080

Entity typeother

Related Parties

1
  • filerCIK 0001834681

Filing Metadata

Form type
4
Filed
Sep 5, 8:00 PM ET
Accepted
Sep 6, 6:30 PM ET
Size
6.5 KB